Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares
24 June 2024 - 1:23AM
PR Newswire (US)
ROCKVILLE, Md. and SUZHOU, China, June 24,
2024 /PRNewswire/ -- Ascentage Pharma (6855.HK) announced
that it has confidentially submitted a draft registration statement
on Form F-1 to the U.S. Securities and Exchange Commission (the
"SEC") relating to the proposed initial public offering of American
depositary shares representing its ordinary shares. The number of
shares to be offered and the price range for the proposed offering
have not yet been determined. The initial public offering is
expected to occur after the SEC completes its review process,
subject to market and other conditions.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities. Any offers,
solicitations or offers to buy, or any sales of securities will be
made in accordance with the registration requirements of the
Securities Act of 1933, as amended ("Securities Act"). This
announcement is being issued in accordance with Rule 135 under the
Securities Act.
Logo -
https://mma.prnewswire.com/media/891219/Ascentage_Pharma_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/ascentage-pharma-announces-confidential-submission-of-draft-registration-statement-for-proposed-initial-public-offering-of-american-depositary-shares-302179764.html
Copyright 2024 PR Newswire